{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:36:57Z","timestamp":1792784217527,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"\u2018100 Foreign Expert\u2019 scheme of the Shanxi province government","award":["R100456"],"award-info":[{"award-number":["R100456"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2018.02.012","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T12:27:53Z","timestamp":1518870473000},"page":"385-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"special_numbering":"C","title":["Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"133","author":[{"given":"Peng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.02.012_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib3","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"6736","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib4","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 Months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J.\u00a0Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib7","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-3806(99)00065-6","article-title":"Glial cell line-derived neurotrophic factor protects midbrain dopamine neurons from the lethal action of the weaver gene: a quantitative immunocytochemical study","volume":"116","author":"Broome","year":"1999","journal-title":"Brain Res. Dev. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/WNR.0000000000000548","article-title":"A\u00a0novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain","volume":"37","author":"Cao","year":"2016","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2174\/1381612043384934","article-title":"Passage of VIP\/PACAP\/secretin family across the blood-brain barrier: therapeutic effects","volume":"10","author":"Dogrukol-Ak","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.55.1.7","article-title":"Pharmacological agents that directly modulate insulin secretion","volume":"55","author":"Doyle","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib17","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/mt.2011.249","article-title":"Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery","volume":"20","author":"Drinkut","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","article-title":"The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer's disease","volume":"228","author":"Duffy","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2011.11.007","article-title":"Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice","volume":"674","author":"Faivre","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-121888","article-title":"D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model","volume":"35","author":"Faivre","year":"2013","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt174","article-title":"Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP\/PS1 mouse model","volume":"5","author":"Faivre","year":"2013","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib23","first-page":"436813","article-title":"Parkinson's disease and systemic inflammation","volume":"2011","author":"Ferrari","year":"2011","journal-title":"Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","article-title":"Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence","volume":"27","author":"Freiherr","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib26","first-page":"133","article-title":"Therapies for the treatment of type 2 diabetes mellitus based on incretin action","volume":"31","author":"Gallwitz","year":"2006","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1074248413501017","article-title":"New and emerging drug molecules against obesity","volume":"19","author":"George","year":"2014","journal-title":"J.\u00a0Cardiovasc. Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s12035-013-8404-z","article-title":"Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders","volume":"47","author":"Ghasemi","year":"2013","journal-title":"Mol. Neurobiol."},{"issue":"19","key":"10.1016\/j.neuropharm.2018.02.012_bib29","first-page":"11","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/en.2014-1675","article-title":"Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain","volume":"156","author":"Heppner","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/XCE.0000000000000087","article-title":"GLP-1 and GIP analogues as novel treatments for Alzheimer's and Parkinson's disease","volume":"5","author":"H\u00f6lscher","year":"2016","journal-title":"Cardiovasc. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1517\/14728214.9.1.155","article-title":"Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors","volume":"9","author":"Holst","year":"2004","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib34","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","article-title":"A\u00a0novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease","volume":"117","author":"Jalewa","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jnc.13736","article-title":"Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells","volume":"139","author":"Jalewa","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/revneuro-2015-0021","article-title":"Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease","volume":"27","author":"Ji","year":"2016","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2015.09.035","article-title":"A\u00a0novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF","volume":"1634","author":"Ji","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier","volume":"18","author":"Kastin","year":"2002","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mds.25344","article-title":"Trophic factor gene therapy for Parkinson's disease","volume":"28","author":"Kordower","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0161-813X(02)00098-0","article-title":"Parkinson's disease: current and future challenges","volume":"23","author":"Langston","year":"2002","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib44","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease","volume":"19","author":"Li","year":"2010","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib47","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejphar.2015.08.038","article-title":"Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease","volume":"765","author":"Liu","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib52","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","article-title":"Molecular pathophysiology of Parkinson's disease","volume":"28","author":"Moore","year":"2005","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-007-0116-y","article-title":"Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation","volume":"9","author":"Moran","year":"2008","journal-title":"Neurogenetics"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00313602","article-title":"Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease","volume":"87","author":"Moroo","year":"1994","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","article-title":"Insulin resistance impairs nigrostriatal dopamine function","volume":"231","author":"Morris","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease","volume":"15","author":"Nagahara","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib59","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib60","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain","volume":"85","author":"Nyberg","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib61","doi-asserted-by":"crossref","first-page":"e58784","DOI":"10.1371\/journal.pone.0058784","article-title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","article-title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","volume":"700","author":"Parthsarathy","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib63","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JAD-2002-4605","article-title":"The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease","volume":"4","author":"Perry","year":"2002","journal-title":"J.\u00a0Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib64","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/WCO.0b013e3283633741","article-title":"Recent developments in biomarkers in Parkinson disease","volume":"26","author":"Schapira","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib65","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc10-1333","article-title":"Diabetes and the risk of developing Parkinson's disease in Denmark","volume":"34","author":"Schernhammer","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","article-title":"A\u00a0novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","volume":"237","author":"Shi","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib67","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/dc11-1511","article-title":"Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications","volume":"35","author":"Sun","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuropharm.2018.02.012_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pneurobio.2006.06.003","article-title":"Insulin signaling in the central nervous system: learning to survive","volume":"79","author":"van der Heide","year":"2006","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib70","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/jnr.21513","article-title":"Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease","volume":"86","author":"Wakamatsu","year":"2008","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2018.02.012_bib71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2015.07.021","article-title":"Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model","volume":"293","author":"Zhang","year":"2015","journal-title":"Behav. Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T16:48:22Z","timestamp":1547138902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":71,"alternative-id":["S0028390818300698"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}